Crowberry inhibits cell proliferation and migration through a molecular mechanism that includes inhibition of DEK and Akt signaling in cholangiocarcinoma

Xue Wang, Xuebing Zhou, Ludan Zhang, Xin Zhang, Chunyu Yang, Yingshi Piao, Jinhua Zhao, Lili Jin, Guihua Jin, Ren‐Bo An, Xiangshan RenChinese 2022 · DOI

This study, published in Chinese Medicine, explores the potential of crowberry (Empetrum nigrum var. japonicum) as a therapeutic agent against cholangiocarcinoma (CCA), a highly aggressive bile duct cancer. By combining chemical profiling, cellular assays, and animal models, the researchers demonstrate that crowberry extract effectively halts tumor growth and metastasis by suppressing the DEK oncoprotein and the Akt/mTOR signaling pathway.

TL;DR

Researchers have identified that crowberry extract significantly inhibits the proliferation and migration of cholangiocarcinoma cells both in the lab and in animal models. The mechanism involves the downregulation of the DEK oncoprotein, which in turn inactivates the PI3K/Akt/mTOR pathway, leading to cancer cell death (apoptosis) and a reversal of the processes that allow cancer to spread.

What Problem Does This Paper Address?

Cholangiocarcinoma (CCA) is a "silent killer" with a dismal prognosis; even with surgery and chemotherapy, the five-year survival rate remains around 15%. Because CCA is often resistant to conventional therapies, there is an urgent need for new treatments with low toxicity.

While crowberry has been used in traditional medicine for its anti-inflammatory and antioxidant properties, its specific efficacy against CCA was unknown. Furthermore, the molecular "wiring" that crowberry targets in cancer cells had never been mapped. This paper seeks to bridge that gap by identifying both the bioactive compounds in crowberry and the specific signaling pathways they disrupt.

Methods

The authors employed a multi-tiered experimental approach:

  • Chemical Profiling: Used HPLC and HPLC–tandem mass spectrometry (MS/MS) to identify the primary bioactive flavonoids in the crowberry extract.
  • Cellular Phenotyping: Assessed cell viability and growth using MTT, colony formation, and EdU assays. They measured "metastatic potential" through wound healing (lateral migration) and Transwell (vertical migration) assays.
  • Molecular Mechanism: Used Western blotting to track changes in protein expression, specifically focusing on apoptosis markers (Bax/Bcl-2), the Akt/mTOR pathway (p-Akt, p-S6, p-4EBP1), and Epithelial-Mesenchymal Transition (EMT) markers (E-cadherin, Vimentin, Snail).
  • Genetic Validation: To prove that the protein DEK was the key target, they used siRNA to "silence" DEK and lentiviral vectors to "overexpress" it, observing how these changes influenced crowberry’s effectiveness.
  • In Vivo Testing: Established a xenograft mouse model using QBC939 cells to observe tumor suppression in a living system.

Datasets

As a biological study, the "data" consists of specific cell lines and animal models:

  • Cell Lines: Human CCA lines (HuCCT1, QBC939, RBE, TFK1) and a normal human bile duct epithelial cell line (HIBEpic) as a control.
  • Animal Model: BALB/C female nude mice (4 weeks old).
  • Bioinformatics: The researchers utilized the UALCAN and GeneMANIA databases to confirm DEK expression levels in human patients and predict interactions between DEK and the Akt pathway.

Key Insights and Ideas

  • DEK as the "Master Switch": The study identifies the DEK oncoprotein as a critical upstream regulator. In CCA, DEK is overexpressed; crowberry effectively turns this switch off, which triggers a cascade of inhibitory effects.
  • Reversing the "Escape" Mechanism: Cancer cells spread via EMT, a process where they lose their "stickiness" (E-cadherin) and become mobile (Vimentin/Snail). Crowberry was found to reverse this, essentially "locking" the cells in place.
  • Dual-Action Attack: Crowberry doesn't just stop cells from dividing (cytostatic); it actively kills them (cytotoxic) by triggering the mitochondrial apoptotic pathway, evidenced by the release of Cytochrome C and the activation of caspases.
  • The DEK-Akt Link: A major "aha moment" was confirming that DEK sits upstream of the Akt/mTOR pathway. When DEK was artificially overexpressed, it rescued the cancer cells from the effects of crowberry, proving that DEK is a primary molecular target of the extract.

Key Results

  • Dose-Dependent Inhibition: Crowberry inhibited CCA cell viability with IC50 values of 87.5 µg/ml (HuCCT1) and 144.1 µg/ml (QBC939).
  • Significant Tumor Reduction: In the mouse model, treatment with 50 mg/kg of crowberry extract led to a dramatic reduction in both tumor volume and weight compared to the control group.
  • Proliferation Crash: The Ki67 index (a marker of how fast cells are dividing) plummeted from 83.2% in the control group to just 7.4% in the crowberry-treated group.
  • Bioactive Identification: The study identified three key flavonoids: 2’-methoxy-4’-hydroxy-dihydrochalcone, 2’,4’-dihydroxy-dihydrochalcone, and 2’,4’-dihydroxy-chalcone.

Limitations and Future Work

While the results are promising, the authors and the nature of the study suggest several areas for further exploration:

  • The "Magic Bullet" Problem: The study used a whole-plant extract. While they identified three flavonoids, they did not test these compounds individually to determine if one is the primary driver or if they work synergistically.
  • Direct Binding: It remains unclear if crowberry compounds bind directly to the DEK protein or if they inhibit the transcription of the DEK gene.
  • Clinical Translation: While the mouse model showed no liver toxicity (via H&E staining), human metabolism is different. Extensive pharmacokinetic and safety studies are needed before this can move toward clinical trials.
  • Bioavailability: The study used intragastric administration in mice; determining how well these compounds are absorbed and maintained in the human bloodstream is a necessary next step.

Summary updated

Abstract

Crowberry inhibits CCA cells proliferation and migration through a molecular mechanism that includes inhibition of DEK and Akt signaling pathway inhibition in vitro and in vivo.
BibTeX
@inproceedings{wang2022crowberry,
  author = {Xue Wang and Xuebing Zhou and Ludan Zhang and Xin Zhang and Chunyu Yang and Yingshi Piao and Jinhua Zhao and Lili Jin and Guihua Jin and Ren‐Bo An and Xiangshan Ren},
  title = {{Crowberry inhibits cell proliferation and migration through a molecular mechanism that includes inhibition of DEK and Akt signaling in cholangiocarcinoma}},
  booktitle = {Chinese},
  year = {2022},
  doi = {10.1186/s13020-022-00623-6},
}
Figure